期刊
SOCIOLOGY OF HEALTH & ILLNESS
卷 40, 期 6, 页码 969-987出版社
WILEY
DOI: 10.1111/1467-9566.12731
关键词
biomedicine; dementia; Alzheimer's; genetic risk; prevention; risk; ethics; bioethics
资金
- Innovative Medicines Initiative Joint Undertaking [115736]
- European Union's Seventh Framework Programme (FP7/2007-2013)
- EFPIA companies'
- Alzheimer's Society
- Pasqual Maragall Foundation
- 'La Caixa' Foundation
- EPAD
Biomedical research aimed at the development of therapies for chronic and late-onset conditions increasingly concentrates on the early treatment of symptom-less disease. This broad trend is evidenced in prominent shifts in contemporary dementia research. Revised diagnostic criteria and new approaches to clinical trials propose a focus on earlier stages of disease and prompt concerns about the implications of communicating test results associated with the risk of developing dementia when no effective treatments are available. This article examines expectations of the implications of learning test results related to dementia risk, based on focus group research conducted in the UK and Spain. It points to the extended social and temporal aspects of the dementia risk experience. Three key dimensions of this risk experience are elaborated: living at risk', represented in efforts to reduce risk and plan for the future; with risk', through vigilance towards cognitive health and earlier or prolonged contact with healthcare services; and finally, beyond risk' through a cessation of the self in its current social, legal and financial form. A virtual abstract of this paper can be viewed at: https://www.youtube.com/channel/UC_979cmCmR9rLrKuD7z0ycA
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据